ArticleMethods in molecular biology (Clifton, N.J.)2026
UbiSite Approach: Global Site-Specific Profiling of Canonical and Non-Canonical Ubiquitination in Cells and Tissues.
Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ubiquitination is a complex post-translational modification that regulates a wide range of cellular processes through the covalent attachment of ubiquitin to substrate proteins. While canonical ubiquitination occurs on lysine residues, non-canonical modifications on serine, threonine, and the protein N-terminus are increasingly recognized. This chapter describes the UbiSite approach, a refined strategy for site-specific mapping of global ubiquitination using mass spectrometry-based proteomics. The method relies on digestion of the proteome of interest with LysC endopeptidase. LysC digestion leaves a 13 amino acid remnant on the ubiquitinated site of modified peptides, and this remnant is recognized by the monoclonal UbiSite antibody allowing selective enrichment of ubiquitinated peptides. Tens of thousands modification sites are readily identified from cells or tissue extracts in a single UbiSite experiment with the workflow described here. The 13 amino acid remnant is unique to ubiquitin and the UbiSite antibody thereby discriminates ubiquitin from other ubiquitin-like modifiers and enables detection of both canonical and non-canonical ubiquitination. The UbiSite procedure can be automated and combined with label-free quantification as well. UbiSite offers a robust and versatile platform for comprehensive ubiquitinome profiling with enhanced specificity and depth, enabling new insights into the regulatory roles of ubiquitin across diverse biological contexts.
Indexed as
Identifiers
42573689What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.